X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EN-2642 is an affinity EGFR-Fc: HER3:Fc ligand trap and binds 9 of 11 growth factors which activate HER family.Growth factors participate in progression of many diseases, including solid cancers and rheumatoid arthritis.
Lead Product(s): EN-2642
Therapeutic Area: Oncology Product Name: EN-2642
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Enosi's Growth Factor Trap (EN-2000 Program) and TNFR1 Blocker (EN1001) were licensed as part of the partnership. Both programs have the potential to be used as cross-over drugs to treat cancer and autoimmune diseases.
Lead Product(s): EN1001
Therapeutic Area: Immunology Product Name: EN1001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Danuo Science Group
Deal Size: $105.0 million Upfront Cash: $5.0 million
Deal Type: Partnership July 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
